Results 131 to 140 of about 3,353 (184)

Real-world use of novel β-lactams in immunologically vulnerable patients: insights from an Italian retrospective cohort. [PDF]

JAC Antimicrob Resist
Bognetti M, Fama F, Conflitti C, Brivio F, Piscaglia M, Schiavini M, Cossu MV, Vimercati S, Rossin E, De Falco T, Pagani C, Rimoldi SG, Gori A, Colaneri M, Palomba E.   +14 more
europepmc   +1 more source

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. [PDF]

J Blood Med
Deng DX, Wang T, Sun H, Kong J, Zhang YY, Cao LQ, Mo XD.   +6 more
europepmc   +1 more source

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients. [PDF]

Curr Opin Infect Dis
Carvalho de Sousa E, Melchio M, Mikulska M.   +2 more
europepmc   +1 more source

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in <i>Pseudomonas aeruginosa</i>. [PDF]

Antimicrob Agents Chemother
González-Pinto L, Monge-Olivares L, Pérez-Rodríguez G, Aja-Macaya P, Sánchez-Peña L, Gomis-Font MA, Rodríguez-Pallares S, Blanco-Martín T, López-Cerero L, Beceiro A, Bogaerts P, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

<i>In vitro</i> activities of aztreonam/nacubactam and cefepime/nacubactam against a global collection of molecularly characterized Enterobacterales isolates carrying carbapenemases: a global antimicrobial resistance surveillance study from 2021 to 2023. [PDF]

JAC Antimicrob Resist
Estabrook M, Suzuki E, Shimizu A, Okade H.   +3 more
europepmc   +1 more source

Targeting KPC-Producing <i>Klebsiella pneumoniae</i> Biofilms: Genomic Profiles, Clinical Outcomes and Novel Combinations. [PDF]

Microorganisms
Papalini C, Bicchieraro G, Tordelli Ruda L, Wong AYW, Battistelli C, Genga G, Tommasi A, Gidari A, Francisci D, Socio GV, Spaccapelo R, Pietrella D, Mencacci A, Monari C, Sabbatini S.   +14 more
europepmc   +1 more source

Update on the comparative <i>in vitro</i> activity of cefiderocol and four β-lactam-β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens. [PDF]

JAC Antimicrob Resist
Wohlfarth E, Deuchert F, Gatermann SG, Higgins PG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G, Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Infection Therapy .   +8 more
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source

Exploring the Effectiveness of Imipenem/Relebactam in Patients with Antimicrobial-Resistant Hospital-Acquired Infections: Findings from Systematic Literature Reviews. [PDF]

Antibiotics (Basel)
Shields RK, Martin-Loeches I, Yücel E, Bagga S, Pal Kaur Khurana V, Soni P, Das P, Cameron C.   +7 more
europepmc   +1 more source

Automated modeling of population pharmacokinetic models using nlmixr2auto: a clinical trial and real-world data study

Huang Z, Fidler M, Nyang’wa B, Standing JF, Kloprogge F.   +4 more
europepmc   +1 more source